Targeted delivery for breast cancer therapy: The history of nanoparticle-albumin-bound paclitaxel

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 8, 2010, Pages 1413-1432

  Petrelli, Fausto ^a   Borgonovo, Karen ^a   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

Breast cancer; Caveolin 1; Gp60; Metastatic disease; Nab paclitaxel; Nanotechnology; SPARC; Taxanes

Indexed keywords

ALBUMIN; ALKYLATING AGENT; ANTIHISTAMINIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; IXABEPILONE; METHOTREXATE; MITOMYCIN; NANOPARTICLE; NAVELBINE; NITROSOUREA; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ASTHENIA; AUTONOMIC NEUROPATHY; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BLURRED VISION; BONE PAIN; BRADYCARDIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CELLULITIS; CHEMISTRY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPARATIVE STUDY; COUGHING; CRANIAL NERVE PARALYSIS; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EYE BURNING; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FIBROSIS; FLUSHING; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEADACHE; HEART ARREST; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HISTORY; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOTENSION; INJECTION SITE REACTION; INTERSTITIAL PNEUMONIA; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; INTRACARDIAC THROMBOSIS; ISCHEMIC COLITIS; KERATITIS; KERATOPATHY; LETHARGY; LUNG EMBOLISM; LUNG FIBROSIS; MALAISE; MELANOMA; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NANOTECHNOLOGY; NAUSEA; NECROSIS; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NEUTROPENIC ENTEROCOLITIS; NONHUMAN; PAIN; PANCREAS CANCER; PANCREATITIS; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHLEBITIS; PNEUMONIA; PNEUMOTHORAX; PROTEINURIA; RADIATION PNEUMONIA; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SINUS BRADYCARDIA; SINUS TACHYCARDIA; SKIN BURNING SENSATION; SKIN EXFOLIATION; SKIN INDURATION; SKIN REDNESS; SKIN TINGLING; SORE THROAT; STOMATITIS; STROKE; SUPRAVENTRICULAR TACHYCARDIA; SYNCOPE; THORAX PAIN; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION; VASCULAR DISEASE; VISUAL DISORDER; VOMITING; WEAKNESS; WOUND HEALING;

ALBUMINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; NANOPARTICLES; NEOPLASM METASTASIS; PACLITAXEL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77952168147     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003796562     Document Type: Review

References (59)

1. Ferguson T, Wilcken N, Vagg R, et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007;CD004421
2. Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008;26:1980-1986
3. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-5217
4. Available from: http://www.abraxane. com/resources/Abraxane-Healthcare- Professional-Prescribing-Information.pdf
5. Windebank AJ, Blexrud MD, de Groen PC. Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther 1994;268:1051-1056
6. Irizarry LD, Luu TH, McKoy JM, et al. Cremophor EL-containing paclitaxel-induced anaphylaxis: a call to action. Community Oncol 2009;132-134
7. Gelderblom H, Verweij J, Nooter K, et al. The drawbacks and advantages of vehicle selectionfor drug formulation. Eur J Cancer 2001;37:1590-1598
8. Authier N, Gillet JP, Fialip J, et al. Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats. Neurotox Res 2001;3:301-306
9. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263-1268
10. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-1044
11. Hennenfent KL, Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol 2006;17:735-749
12. Desai NP, Trieu V, Hwang LY, et al. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008;19:899-909
13. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-1324
14. Chin D, Boyle GM, Williams RM, et al. Novel markers for poor prognosis in head and neck cancer. Int J Cancer 2005;113:789-797
15. Koukourakis MI, Giatromanolaki A, Brekken RA, et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 2003;63:5376-5380
16. Watkins G, Douglas-Jones A, Bryce R, et al. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids 2005;72:267-272
17. Von Hoff D, Ramanathan E, Borad M, et al. SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: a phase I/II study [abstract 4525]. J Clin Oncol 2009;27(Suppl):15s
18. Markovic SN, Suman VJ, Kottschade LA, et al. A phase II trial of carboplatin (C) and nab-paclitaxel (ABI-007-nab-P) in patients with unresectable stage IV melanoma: final data from N057E [abstract 9055]. J Clin Oncol 2009;27(Suppl):15s
19. Mirtsching B, Cosgriff T, Harker G, et al. Single-agent nab-paclitaxel given weekly (3/4) as first-line therapy for metastatic breast cancer (an International Oncology Network study, #I-04-012). J Clin Oncol 2008;26(Suppl):abstract 1118
20. Volk LD, Flister MJ, Bivens CM, et al. Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia 2008;10:613-618
21. Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005;23:7785-7793
22. Cuppone F, Bria E, Carlini P, et al. Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cancer 2008;113:238-246
23. Berstein JA, Mehta R. In vivo response-adapted dose-dense (dd) doxorubicin and cyclophosphamide (AC) ← weekly carboplatin and albumin-bound paclitaxel (nab-TC)/trastuzumab (H)/bevacizumab (B) in large and inflammatory breast cancer (BC): a phase II study. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(Suppl):18S:11078
24. Gradishar WJ, Tjulandin S, Davidson N, et al. Superior efficacy of albumin-bound paclitaxel, ABI-007, compared with polyethylated castor oil-based paclitaxel in women with metastatic breast cancer: results of a Phase III trial. J Clin Oncol 2005;23:1-10
25. Davidson N, Tjulandin S, O'shaughnessy J, et al. Overall survival analysis of a randomized phase III trial comparing nab-paclitaxel with solvent-based paclitaxel in patients with metastatic breast cancer previously treated with anthracycline. Eur J Cancer 2008;218(Suppl 6):abstract 569
26. Vukelja SJ, O'shaughnessy J, Krasnojon D, et al. Efficacy of Nab-paclitaxel in patients with poor prognostic factors or with anthracycline-resistant metastatic breast cancer (MBC). J Clin Oncol 2008;26(Suppl):abstract 108242
27. Guan Z, Feng F, Li QL, et al. Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(Suppl 18S):1038
28. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009;27:3611-3619
29. Ibrahim NK, Samuels B, Page R, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005;23:6019-6026
30. Blum JL, Savin MA, Edelman G, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007;7:850-856
31. Roy V, LaPlant BR, Gross GG, et al; North Central Cancer Treatment Group. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 2009;20:449-453
32. Somer BG, Schwartzberg LS, Arena F, et al. Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(Suppl 18S):1053
33. Danso MA, Blum JL, Robert NJ, et al. Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer. J Clin Oncol 2008;26(Suppl):abstract 1075
34. Gluck S, Lobo C, Reis I, et al. Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC). J Clin Oncol 2008;26(Suppl): abstract 1089
35. Conlin AK, Hudis CA, Bach A, et al. Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC). J Clin Oncol 2009;27(Suppl 15s);abstract 1006
36. Seidman AD, Conlin AK, Bach A, et al. Phase II study of weekly nanoparticle albumin bound (nab)paclitaxel with carboplatin and trastuzumab as 1st-line therapy for HER2-positive metastatic breast cancer (MBC). J Clin Oncol 2008;26(Suppl):abstract 1047
37. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778-85 Erratum in: J Clin Oncol 2008;26:2793
38. Inhorn RC, Daniel B, Daniel D, et al. Correlation of SPARC, ER, PR, and HER2 tumor with progression-free survival from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nab-paclitaxel. J Clin Oncol 2009;27(Suppl 15s):abstract 618
39. Paz IB, Lau S, Garberoglio C, et al. Nab-paclitaxel and carboplatin with or without trastuzumab (trast) as part of neoadjuvant chemotherapy (NCT) in patients with stage II -- III breast cancer (BC). J Clin Oncol 2008;26(Suppl):abstract 567
40. Yardley DA, Raefsky E, Castillo R, et al. Results of a multicenter pilot study of weekly nab-paclitaxel, carboplatin with bevacizumab, and trastuzumab as neoadjuvant therapy in HER2+ locally advanced breast cancer with SPARC correlatives. J Clin Oncol 2009;27(Suppl 15s):abstract 527
41. Robidoux A, Buzdar AU, Quinaux E, et al. A phase II neoadjuvant trial of sequential weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/ cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer 2010;10:81-86
42. Veerapaneni A, Boisvert M, Choi A, Aggarwal A. Capecitabine and ABI-007 chemotherapy as neoadjuvant treatment of locally advanced breast cancer. J Clin Oncol 2008;26(Suppl):abstract 11535
43. Dickler MN, Traina T, Panageas K, et al. Adjuvant (adj) bevacizumab (B) plus dose-dense (dd) doxorubicin/ cyclophosphamide (AC) followed by nanoparticle albumin- bound paclitaxel (nab-p) in early stage breast cancer (BC) patients (pts): cardiac safety. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(Suppl 18S):567
44. McArthur HL, Rugo H, Nulsen B, et al. Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/ cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer [abstract 4104]. San Antonio, TX. Breast Cancer Symposium 10 -- 15 December; 2008
45. Pippen J, O'shaughnessy J, Krekow L, et al. Adriamycin plus cytoxan followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study [abstract 0151]. 11th International Conference on Primary Therapy of Early Breast Cancer; 11 -- 14 March 2009; St Gallen, Switzerland
46. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439
47. Pippen J, Paul D, Richards D, et al. Dose-dense nab-paclitaxel vs paclitaxel with bevacizumab following adriamycin and cytoxan is safe as adjuvant therapy in patients with early-stage breast cancer [abstract 0152]. 11th International Conference on Primary Therapy of Early Breast Cancer; 11 -- 14 March 2009; St Gallen, Switzerland
48. Jones S, Holmes FA, O'shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol 2009;27:1177-1183
49. Raefsky E, Inhorn R, Lange M, et al. Preliminary safety results from a multicentre phase II trial of nanoparticle-albumin bound paclitaxel/ cyclophsphamide in early breast cancer plus trastuzumab in HER-+ patients (pts). J Clin Oncol 2009;27(Suppl 15s):abstract e11509
50. Dranitsaris G, Coleman R, Gradishar W. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Res Treat 2010;119(3):717-724
51. Hnasko R, Lisanti MP. The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol Interv 2003;3:445-464
52. Pinilla SM, Honrado E, Hardisson D, et al. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat 2006;99:85-90
53. Savage K, Lambros MB, Robertson D, et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 2007;13:90-101
54. Savage K, Leung S, Todd SK, et al. Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res Treat 2008;110:245-256
55. Elsheikh SE, Green AR, Rakha EA, et al. Caveolin 1 and caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer 2008;99:327-334
56. Witkiewicz AK, Dasgupta A, Sotgia F, et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 2009;174:2023-2034 Epub 2009 May 1
57. Carver LA, Schnitzer JE. Caveolae: mining little caves for new cancer targets. Nat Rev Cancer 2003;3:571-581
58. Gradishar WJ, Tjulandin S, Davidson N, et al. Superior efficacy of albumin-bound paclitaxel, ABI-007, compared with polyethylated castor oil-based paclitaxel in women with metastatic breast cancer: results of a Phase III trial. J Clin Oncol 2005;23(31):1-10
59. Available from: http://nano.cancer.gov